Healthcare provider profile · identity verified

Michael Mel Walger, MD

Emergency Medicine · BOSTON, MA · NPI 1225142110

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Trazodone Hcl	Trazodone Hcl	251	46
Gabapentin	Gabapentin	233	38
Atorvastatin Calcium	Atorvastatin Calcium	223	42
Eliquis	Apixaban	218	22
Amlodipine Besylate	Amlodipine Besylate	170	30
Furosemide	Furosemide	132	17
Mirtazapine	Mirtazapine	129	25
Sertraline Hcl	Sertraline Hcl	121	17
Omeprazole	Omeprazole	117	27
Metoprolol Succinate	Metoprolol Succinate	102	24
Quetiapine Fumarate	Quetiapine Fumarate	96	13
Levothyroxine Sodium	Levothyroxine Sodium	85	15
Divalproex Sodium	Divalproex Sodium	80	12
Xarelto	Rivaroxaban	79	suppressed
Lisinopril	Lisinopril	78	18
Buspirone Hcl	Buspirone Hcl	77	12
Tamsulosin Hcl	Tamsulosin Hcl	76	16
Famotidine	Famotidine	72	16
Potassium Chloride	Potassium Chloride	64	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	63	11
Pantoprazole Sodium	Pantoprazole Sodium	58	13
Enoxaparin Sodium	Enoxaparin Sodium	53	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	51	suppressed
Losartan Potassium	Losartan Potassium	51	suppressed
Ondansetron Hcl	Ondansetron Hcl	50	23
Donepezil Hcl	Donepezil Hcl	49	11
Citalopram Hbr	Citalopram Hydrobromide	45	suppressed
Torsemide	Torsemide	42	suppressed
Vancomycin Hcl-0.9% Nacl	Vancomycin/0.9 % Sod Chloride	40	suppressed
Baclofen	Baclofen	39	suppressed
Diclofenac Sodium	Diclofenac Sodium	38	14
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	38	suppressed
Simvastatin	Simvastatin	37	suppressed
Duloxetine Hcl	Duloxetine Hcl	35	suppressed
Nuplazid	Pimavanserin Tartrate	35	suppressed
Nyamyc	Nystatin	35	14
Clopidogrel	Clopidogrel Bisulfate	34	suppressed
Metformin Hcl	Metformin Hcl	34	suppressed
Jardiance	Empagliflozin	33	suppressed
Midodrine Hcl	Midodrine Hcl	33	suppressed
Prednisone	Prednisone	33	14
Hydroxyzine Hcl	Hydroxyzine Hcl	32	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	31	suppressed
Prazosin Hcl	Prazosin Hcl	30	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	29	suppressed
Vancomycin Hcl	Vancomycin Hcl	28	suppressed
Allopurinol	Allopurinol	27	suppressed
Olanzapine	Olanzapine	27	suppressed
Amiodarone Hcl	Amiodarone Hcl	26	suppressed
Trulicity	Dulaglutide	26	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	25	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	25	suppressed
Bupropion Hcl Sr	Bupropion Hcl	24	suppressed
Fluticasone Propionate	Fluticasone Propionate	24	13
Levetiracetam	Levetiracetam	24	suppressed
Myrbetriq	Mirabegron	24	suppressed
Valsartan	Valsartan	24	suppressed
Amantadine	Amantadine Hcl	23	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	23	suppressed
Risperidone	Risperidone	23	suppressed
Sucralfate	Sucralfate	23	suppressed
Hydralazine Hcl	Hydralazine Hcl	22	suppressed
Hydrocortisone	Hydrocortisone	22	suppressed
Bupropion Xl	Bupropion Hcl	21	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	21	12
Methocarbamol	Methocarbamol	21	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	20	13
Aripiprazole	Aripiprazole	20	suppressed
Spironolactone	Spironolactone	20	suppressed
Clozapine	Clozapine	19	suppressed
Entacapone	Entacapone	19	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	19	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Metformin Hcl Er	Metformin Hcl	19	suppressed
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	19	suppressed
Glipizide Er	Glipizide	18	suppressed
Haloperidol	Haloperidol	18	suppressed
Latanoprost	Latanoprost	18	suppressed
Mexiletine Hcl	Mexiletine Hcl	18	suppressed
Mupirocin	Mupirocin	16	suppressed
Spiriva Handihaler	Tiotropium Bromide	16	suppressed
Benztropine Mesylate	Benztropine Mesylate	15	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	15	suppressed
Finasteride	Finasteride	15	suppressed
Ibuprofen	Ibuprofen	15	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	suppressed
Xifaxan	Rifaximin	15	suppressed
Insulin Lispro	Insulin Lispro	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Montelukast Sodium	Montelukast Sodium	14	suppressed
Carvedilol	Carvedilol	13	suppressed
Daptomycin	Daptomycin	13	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	13	suppressed
Lokelma	Sodium Zirconium Cyclosilicate	13	suppressed
Neupro	Rotigotine	13	suppressed
Risperidone Er	Risperidone Microspheres	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	13	suppressed
Airsupra	Albuterol Sulfate/Budesonide	12	suppressed
Albuterol Sulfate	Albuterol Sulfate	12	suppressed
Carbamazepine	Carbamazepine	12	suppressed
Celecoxib	Celecoxib	12	suppressed
Cephalexin	Cephalexin	12	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Metronidazole	Metronidazole	12	suppressed
Naproxen	Naproxen	12	suppressed
Propranolol Hcl Er	Propranolol Hcl	12	suppressed
Bumetanide	Bumetanide	11	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	11	suppressed
Incruse Ellipta	Umeclidinium Bromide	11	suppressed
Labetalol Hcl	Labetalol Hcl	11	suppressed
Lamotrigine	Lamotrigine	11	suppressed
Oxcarbazepine	Oxcarbazepine	11	suppressed
Oxycodone Hcl	Oxycodone Hcl	11	suppressed
Ozempic	Semaglutide	11	suppressed
Santyl	Collagenase Clostridium Hist.	11	suppressed
Warfarin Sodium	Warfarin Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error